Crossmark

Real-World Analysis of Healthcare Utilization, Treatment Patterns, and Economic Burden in Medicare Beneficiaries with Parkinson’s Disease: Implications by Levodopa Formulation and Disease Severity

Crossref DOI link: https://doi.org/10.1007/s41669-025-00588-w

Published Online: 2025-06-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Arnold, Renée J. G. https://orcid.org/0000-0001-5935-3220
Tse, Winona

Martin, Kimberly

Kuan, Renee
Funding

Funding for this research was provided by:

Amneal Pharmaceuticals
License Information

Text and Data Mining valid from 2025-06-16

Version of Record valid from 2025-06-16
More Information

Article History

Accepted: 25 May 2025

First Online: 16 June 2025

Declarations

:

: We gratefully acknowledge the basic funding of this research by Amneal Pharmaceuticals, Inc. There was no funding for the writing or review of this manuscript.

: Renée Arnold is an editorial board member of PharmacoEconomics - Open. She was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. No other authors report conflicts of interest or competing interests.

: The Institutional Review Board of the Mount Sinai School of Medicine approved this research under HS no. 20-01204 GCO no. 1: 20-2516.

: Not applicable.

: Not applicable.

: No raw data can be provided per our Data Use Agreement with ResDAC.

: Not applicable.

: R.J.A. conceived of the study and wrote multiple drafts of the manuscript; W.T. reviewed the data and provided comments on the manuscript drafts; R.K. provided writing assistance on the manuscript; and K.M. provided statistical assistance and reviewed/commented on the manuscript drafts.

Document is current

Any future updates will be listed below